Chat IA
Loading data for BRGX — first visit, this takes a few seconds.

BioRegenx, Inc.

BRGX · OTC Markets OTCPK · USD

0.01 +0.00 (0.00%)

À la clôture : Sep 11, 2026, 8:00 PM

Volume
108K

BioRegenx, Inc. (BRGX) : cours, analyse et données

Valeur intrinsèque

Chargement de la valeur intrinsèque…

Prévisions des analystes

Prévisions boursières →

Prévisions des analystes indisponibles

Objectif à 12 mois · n/a analystes

Consensus des analystes : n/a

Intervalle:1D
Chargement des bougies et signaux…

Performance financière

Voir les finances →

Chargement...

Derniers résultats

SignaléÉcart estiméChangement d’une année sur l’autre
Chiffre d’affairesn/an/a
EPSn/an/a

Prochains résultats

Voir les résultats détaillés →

Métriques

Cours acheteur
0.01
Résultat net (ttm)
-1.3M
-2.71
0
n/a
n/a
P/B (ttm)
-1.04
P/S (ttm)
2.86
Date des résultats
n/a
Cours vendeur
0.01
Volume
108,190
Volume moy. (20D)
15,837
Ouverture
0.01
Clôture précédente
0.01
Fourchette du jour
0.00 - 0.01
Intervalle de 52 semaines
0.00 - 0.03
Date ex-dividende
n/a
Aucun article d’actualité disponible pour l’instant

À propos de BioRegenx, Inc.

Voir le profil →
BioRegenx, Inc. engages in the research, development, and commercialization of dietary supplements, medical devices, software, and contactless diagnostic technologies in the United States and internationally. The company offers DocSun AI engine, which integrates with a ballistocardiograph that detects an individual's heartbeat; TruScan.AI mobile app for additional health indications; VitalWellness app for DNA and epigenetics platform; and Endocalyx Pro, a dietary supplement targeting microvascular capillary health. It also provides MyBodyRx, a supplement; GlycoCheck software and medical devices; hydrogen water products and health and wellness devices, such as pulsed electro-magnetic field devices; StimaWELL and ReLounge electronic muscle stimulation therapy devices; and Findit.com, a social media content management platform. The company sells its products through a direct selling channel to health professionals and research organizations. BioRegenx, Inc. is headquartered in Chattanooga, Tennessee. Health Information Services · Healthcare

BioRegenx, Inc. engages in the research, development, and commercialization of dietary supplements, medical devices, software, and contactless diagnostic technologies in the United States and internationally. The company offers DocSun AI engine, which integrates with a ballistocardiograph that detects an individual's heartbeat; TruScan.AI mobile app for additional health indications; VitalWellness app for DNA and epigenetics platform; and Endocalyx Pro, a dietary supplement targeting microvascular capillary health. It also provides MyBodyRx, a supplement; GlycoCheck software and medical devices; hydrogen water products and health and wellness devices, such as pulsed electro-magnetic field devices; StimaWELL and ReLounge electronic muscle stimulation therapy devices; and Findit.com, a social media content management platform. The company sells its products through a direct selling channel to health professionals and research organizations. BioRegenx, Inc. is headquartered in Chattanooga, Tennessee.

Secteur Healthcare
Date d’introduction Feb 15, 2002
Employés 6
Bourse OTC Markets OTCPK
Symbole boursier BRGX